


Drug decreases gut leakiness associated with ulcerative colitis

December 4 2019, by Iqbal Pittalwala



Declan McCole (right) and his graduate student Anica Sayoc-Becerra are seen here examining a culture flask of intestinal epithelial cells prior to treating them with tofacitinib. Credit: I. Pittalwala, UC Riverside.

A research team led by biomedical scientists at the University of California, Riverside, has found that a drug approved by the FDA to

treat rheumatoid arthritis and ulcerative colitis can repair permeability defects in the gut's epithelium.

Affecting roughly 1 million Americans, [ulcerative colitis](#) is a chronic inflammatory bowel [disease](#) of the large intestine in which the lining of the colon becomes inflamed and leaky. Affecting more than 2 million Americans, [rheumatoid arthritis](#) is an autoimmune disease in which the body's [immune system](#) attacks the joints.

The [study](#) is the first to show the drug, tofacitinib, also called Xeljanz, has a direct effect on [cells](#) lining the gut by correcting defects that occur in inflammation. Until now, the effects of tofacitinib on intestinal epithelial cell functions were largely unknown.

"Our work increases our understanding of how this drug is useful for treating ulcerative colitis," said Declan McCole, a professor of biomedical sciences in the UCR School of Medicine, and the lead author of the [study](#) that appears in the journal *Inflammatory Bowel Diseases*. "We now better understand where in the gut the drug is working, and how."

McCole explained that increased intestinal permeability—or leakiness—is a feature of ulcerative colitis and plays a critical role in promoting inflammation. His team tested tofacitinib in human intestinal epithelial cell lines, as well as in organoids, or colonoids, that were derived from primary human colonic stem cells isolated from human subjects—primarily patients undergoing elective colonoscopy for colon cancer screening—and found tofacitinib repaired inflammation-induced permeability defects in both.

The epithelium is a thin layer that lines the alimentary canal. The gastrointestinal epithelium is comprised of cells that have gaps between them, making them selectively permeable and providing a barrier that

keeps out pathogens, toxins, and antigens from entering the gut, while allowing the absorption of nutrients. In ulcerative colitis, this epithelial permeability becomes leaky, allowing bacterial products to cross into the gut and nutrients and water to leak out. This, in turn, triggers immune responses, resulting in fluid loss and diarrhea.

"We found tofacitinib fixes the leakiness in the intestinal barrier," McCole said. "Specifically, it fixes intestinal epithelial permeability defects caused by 'interferon-gamma,' an inflammatory cytokine involved in autoimmune diseases such as ulcerative colitis and rheumatoid arthritis."

"By targeting specific molecules, the drug inhibits a pathway that is activated by inflammation," said Anica Sayoc-Becerra, a [graduate student](#) in the Biomedical Sciences Graduate Program, a member of McCole's lab, and the first author of the research paper. "Our study shows tofacitinib is not just acting on immune cells, as was first thought, but can have a direct effect on the epithelial cells that are the key factor in maintaining gut barrier function."

A major focus of McCole's lab is PTPN2, a protein-coding gene associated with [autoimmune diseases](#) such as Crohn's disease, ulcerative colitis, and rheumatoid arthritis. Individuals with mutations in this gene that cause it to lose function have an increased risk of getting these diseases. McCole's research group was the first to identify PTPN2 normally helps to protect the barrier function of the epithelial cells that line the gut.

"A patient that has a PTPN2 loss-of-function mutation is predicted to have a leakier gut," McCole said. "Rather than trying to repair PTPN2, my lab was successful in inhibiting some of the consequences of the loss-of-function mutation in this gene."

Sayoc-Becerra explained PTPN2 deactivates the same signaling pathway as tofacitinib.

"We thought tofacitinib might be a very effective way of correcting the defects that occur from the loss-of-function mutations of PTPN2 without having to introduce new genes into a cell, animal, or patient," she said.

McCole and Sayoc-Becerra were joined in the [study](#) by UC Riverside's Moorthy Krishnan, Jossue Jimenez, Rebecca Hernandez, Kyle Gibson, and Reyna Preciado; as well as Shujun Fan and Grant Butt of the University of Otago in New Zealand. Sayoc-Becerra expects to graduate with her doctoral degree in December 2019. This is her first paper as first author.

Next, the researchers plan to identify specific patients who may derive the greatest benefit from the drug. This will allow more targeted treatment of patients likely to be good responders to [tofacitinib](#) in a "personalized medicine" approach to treating this disease.

Provided by University of California - Riverside

Citation: Drug decreases gut leakiness associated with ulcerative colitis (2019, December 4) retrieved 25 April 2024 from <https://medicalxpress.com/news/2019-12-drug-decreases-gut-leakiness-ulcerative.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--